Notably, these associations were also observed in a range of observational analyses in agreement with previous evidence.58 FURIN is currently being explored as a drug target, with several phase 1 and 2 clinical trials investigating FURIN inhibitors for cancer immunotherapy showing promising efficacy and a good safety profile.59 Our PheWAS analysis supports the safety of targeting FURIN, though no clinical trials have yet investigated its therapeutic potential for CVD. This evidence concerns the gene FURIN and cancer.